US/UK/Canada

Share

Quotes

This project with Amicogen is incredibly interesting and creates very good conditions for a deeper collaboration in the future. With this agrement, Amicogen and Bio-Works will establish the first local production of agarose-based resins in South Korea
says Jonathan Royce, CEO at Bio-Works Technologies.
Pick a time period -
Tags ( Active)

GoBio™ - new product line saves time in biotherapeutic production

Today, Bio-Works has launched GoBio, a product line of prepacked chromatography columns designed to span the entire production cycle from process development to commercial production. Prepacked columns enable the user to skip the time consuming and technically complex operation of manually packing resin in columns. By using turnkey products, packed by specialists, up to 5 days can be saved in a production run, and simultaneously a consistent and high level of quality is ensured.”We are very proud to launch this product line. Prepacked formats are an important puzzle piece which, when

Bio-Works confirms order from new production customer for oligonucleotide manufacturing

Today, Bio-Works Technologies AB  has confirmed an order worth 2.3 MSEK for WorkBeads chromatography resins to be used in the manufacture of oligonucleotides. The customer is an American contract manufacturer who offers cGMP manufacturing to other pharmaceutical companies. They are part of a larger American conglomerate with 17 000 employees globally. Delivery is planned early in the third quarter of this year.”For over a year, we have said that there are opportunities for Bio-Works to expand on our success with peptides in the oligo market. This order confirms that our theory is correct,”

A strong first quarter for Bio-Works

Bio-Works Technologies. Update Q1-2022. Today, Bio-Works Technologies AB reports sales for the first quarter of 2022—a strong quarter in line with the company’s plan. Product sales reached 6.0 MSEK, an increase of 135% as compared to the same period one year ago. Backlog increased to 8.4 MSEK, from 6.9 MSEK at the start of the year.”We are very happy with our performance in Q1,” said Jonathan Royce, CEO at Bio-Works. ”Sales growth continues to increase according to plan and we have added new customers in the US, India and Europe during the past three months. Our backlog at the start

Bio-Works is now recertified according to ISO 9001:2015

During 2021, Bio-Works has worked to continuously update its quality management system in accordance with the international standard ISO 9001: 2015. In March, it was confirmed that Bio-Works has met the high standards and the company is now again approved and re-certified."We are very happy and proud that the re-certification of ISO 9001: 2015 has now been approved and the certificate has been updated. A strong, cross-functional team effort by Bio-Works employees made it possible for us to deliver a first-class audit," says Jonatan Svedmyr, Director of Quality Assurance, at Bio-Works.

New order of WorkBeads - the next generation of protein purification - to Spanish CDMO 3P Biopharmaceuticals

Bio-Works confirms a new order of WorkBeads, the company's product line for advanced protein purification, to the Spanish contract and manufacturing organization 3P Biopharmaceuticals. The order has been received via Swedish biotech company Toleranzia and the value amounts to SEK 1.3 million."Bio-Works is very pleased to be able to support 3P Biopharmaceutics in their mission to deliver advanced drugs to improve lives," says Jonathan Royce, CEO of Bio-Works Technologies. This order also confirms that our investment in continued establishment in Europe is progressing according to plan.”

Bio-Works signs distributor agreement with Brennan & Co for the Irish and Northern Irish markets

Bio-Works Technologies AB has signed a sole distributor agreement with Brennan & Co for both the Republic of Ireland and Northern Ireland. Under the terms of the agreement, Brennan & Co will market, sell and distribute WorkBeads, Bio-Works' next-generation protein purification products, to its customers. Brennan & Co thus have access to a competitive product catalogue for the purification of a wide range of biomolecules.“Through Brennan & Co, Bio-Works now has the opportunity to build closer relationships and offer local support to academic and biopharmaceutical customers across Ireland.

Bio-Works confirms new order for delivery of WorkBeads to the Russian market

· Today, Bio-Works has confirmed a new order of WorkBeads – a third-generation chromatography resin—to an end user in the Russian Federation. · The order, received via Fizlabpribor, Bio-Works’ exclusive distributor in Russia, is for WorkBeads affimAb, a product used in the purification of monoclonal antibodies. · Delivery is confirmed for the second quarter of 2022 and the order value exceeds 350 000 EUR.”Bio-Works and Fizlabpribor have a long and mutually-beneficial relationship and we are happy that our collaboration is now strengthened,” said Jonathan Royce, CEO at Bio-Works. “This

Bio-Works confirms new order from Nemysis Limited worth 2.1 million SEK

Bio-Works Technologies AB has confirmed that they have received a new order from Nemysis Limited, an Irish based company developing enzymatic solutions for gluten intolerance. The order, worth €203K (2.1 million SEK) is confirmed for delivery in the fourth quarter of this year.“We are proud that Nemysis Limited has chosen Bio-Works to supply purification solutions for their production. Nemysis and Bio-Works are both companies which are working to develop and commercialize novel technologies,” said Jonathan Royce, CEO of Bio-Works Technologies.”As such, it is exciting that the Bio-Works

Amicogen Inc enters into agreement to divest its ownership in Bio-Works

Amicogen Inc. has entered into an agreement to divest its ownership in Bio-Works Technologies AB (BIOWKS.ST). Amicogen's entire holding of 3,007,896 shares was sold today at 12:03:42 CET in a transaction brokered by Erik Penser Bank for a price of 15.75 SEK. As of June 30, 2021, Amicogen Inc. was Bio-Works' second largest shareholder. The block was primarily sold to Nortal Investments AB and Calyptra AB. As of June 30, 2021, Nortal Investments AB was Bio-Works largest shareholder, owning 4,119,885 shares, or 13.6% of the company.  Dr. Shin, CEO of Amicogen Inc., stated “Amicogen was an

Bio-Works adds distributor coverage in Croatia and Slovenia in deal with BIA d.o.o.

Bio-Works Technologies AB (Uppsala, Sweden) and BIA d.o.o. (Ljubljana, Slovenia) have signed a distribution agreement through which BIA will provide Bio-Works' next generation chromatography resins and prepacked columns to customers in Croatia and Slovenia.  Bio-Works' patented resins, WorkBeads™, are well-suited not only for the purification of biological compounds at laboratory scale but also for biopharmaceuticals at large scale, including peptides and recombinant proteins. Bio-Works has a broad portfolio of resin technology, including immobilized affinity chromatography (IMAC), size

Aptamer Group and Bio-Works Technologies partner to enable improved solutions for gene therapy manufacturing

York, UK and Uppsala, Sweden (August 25, 2021) Aptamer Group Ltd , the developer of custom affinity tools to enable the life science industry through its proprietary Optimer platform, and Bio-Works Technologies AB , the developer and manufacturer of leading-edge agarose-based purification technologies, today announce that they have entered into an agreement to co-develop a new affinity resin for improved purification and scale up of gene therapy vectors.  Under the agreement, Aptamer Group will develop an Optimer™ ligand capable of

Bio-Works confirms two new orders from contract manufacturer Catalent Biologics

Bio-Works Technologies AB has confirmed that they have received two new orders from contract manufacturer Catalent Biologics for a total order value of 778 KSEK (94,512 USD). The orders are expected to ship in the second half of this year. “We are proud that Catalent Biologics has chosen Bio-Works to supply chromatography resins for this project. Catalent Biologics is a fast-growing, global contract manufacturer with innovative technologies and integrated solutions that are leveraged by companies ranging from small biotech to large biopharma. Their deep expertise and patient first

Bio-Works signs distribution agreement with S. Amit Speciality Chemicals in Mumbai, India

Bio-Works Technologies AB  has signed a non-exclusive Distribution Agreement with S. Amit Speciality Chemicals Private Limited  to import, store, distribute, market, promote and sell products within India, Bangladesh, Nepal and Sri LankaBio-Works is strengthening its presence in India by engaging a long-established, leading, full-service Chemistry Solutions provider in India. S. Amit Speciality Chemicals Pvt. Ltd., is part of the S. Amit Group of Companies, headquartered in Mumbai and established 70 years ago. S. Amit is a full-service

Bio-Works signs exclusive distribution agreement with MicroAnalytix in Australia and New Zealand

Bio-Works Technologies AB has signed an exclusive Distribution Agreement with Microanalytix Pty Ltd for the import, storage, distribution, marketing and sales of WorkBeads resins and pre-packed BabyBio and OptioBio columns in Australia and New Zealand.Bio-Works  is strengthening its presence in Australasia by engaging a well-respected laboratory supply company, MicroAnalytix , established in 1988. Bio-Works next-generation agarose resins, WorkBeads™, are well-suited not only for the purification of biological compounds at

Bio-Works launches two new kits for peptide purification

In order to improve the convenience of the resin screening process, Bio-Works announces the launch of two new products, BabyBio™ IEX Screening Kit and BabyBio Peptide Purification Kit.One of the drug development areas that has witnessed an explosion in recent years is that of peptide drugs.  Between 2016 and 2020, 18 drugs containing peptides have been approved by the US FDA. In addition, several hundred are in clinical phases or advanced preclinical studies. It can be a complicated process to find the optimal conditions for ion exchange purification of a new peptide or protein and time

Bio-Works signs licensing agreement with Amicogen Inc to establish local manufacturing of agarose resins in South Korea

· Bio-Works Technologies AB has signed a licensing agreement with Amicogen Inc to establish local production of agarose resins in South Korea  · The contract provides up-front and milestone payments of $5 million USD and royalty payments thereafter on Amicogen’s net sales · Bio-Works existing sales in South Korea are less than 1 million SEK per year, which means that the deal is overwhelmingly positive in terms of revenue and financial outcome for 2021The agreement entails a technology transfer from Bio-Works to Amicogen to establish in-country production of chromatography products in

Bio-Works signs distribution agreement with Yong Chien Technology Inc. in Taiwan

Bio-Works Technologies (Nasdaq First North) has signed a Distribution Agreement with Taipei-based Yong Chien Technology Inc. The agreement covers import, storage, distribution, marketing promotion and sales of WorkBeads resins and pre-packed BabyBio and OptioBio columns in Taiwan.Bio-Works  is strengthening its presence in Taiwan by engaging a well-respected local distributor with years of experience of supplying downstream bioprocessing solutions to academia, research institutes and the growing domestic biotech, biosimilar and biopharma industry. Bio-Works

Bio-Works provides WorkBeads Protein A to Yumab for screening of antibody candidates now in early clinical testing against COVID-19

As a response to the COVID-19 outbreak in the spring of this year, Bio-Works offered to help by providing resins for vaccine purification research. One such project has now resulted in a neutralizing monoclonal antibody candidate against SARS-CoV-2 being produced for clinical phase 1 testing. More than 10 companies took advantage of Bio-Works’ offer of WorkBeads resins and expert advice to help speed up vaccine or treatment development against COVID-19. One of these was Yumab, a Contract Research Organization (CRO) working in a consortium together with Boehringer Ingelheim. Bio-Works

Bio-Works continues investing in the Indian market with BioLinx India as distributor and Dr Ravi Rayanade as Director Regional Sales, India

Bio-Works Technologies (Nasdaq First North) recently signed a distribution agreement with BioLinx India Pvt Ltd, Mumbai, to import, distribute, promote and sell all its products in India to Academia, Hospitals & Clinics and Biotech SMEs. Bio-Works has also engaged Dr Ravi Rayanade as Director Regional Sales. Dr Rayanade is a seasoned bioprocess expert with a wide network in the Indian biotech industry.Bio-Works is further strengthening its presence in the Indian market to take advantage of the many opportunities arising from local companies’ expertise in developing new vaccines and

Bio-Works signs agreement with BioInno Biosciences Co, Ltd to co-develop Asian markets and provide application and technical support

Bio-Works Technologies (Nasdaq First North) has signed a Supply and Reference Customer Agreement with the Jiangsu province-headquartered BioInno Bioscience Co., Ltd. The agreement covers development of the mainland Chinese and Asian markets by jointly providing technical expertise in downstream processing application development that showcases product benefits.Bio-Works is deepening its commitments in China and across Asia, by entering a second Supply and Reference Customer agreement with a local CDMO, BioInno Bioscience Co Ltd, located in the outskirts of Suzhou, Jiangsu province. By

Bio-Works launches two new resins for protein purification: WorkBeads NiMAC and WorkBeads Dsalt

Bio-Works is constantly striving to develop new products that address customer needs and that are differentiated from existing products on the market. Today Bio-Works announces the launch of two new products, WorkBeads™ NiMAC with high resistance to reducing agents such as DTT and chelating substances such as EDTA, and WorkBeads Dsalt designed to enable quick and easy separations of high and low molecular weight substances.WorkBeads NiMAC resin is precharged with very strongly bound nickel ions, allowing purification of His-tagged proteins from sources such as eukaryotic cell extracts, that

Jonathan Royce joins Bio-Works AB as CEO

This week, Jonathan Royce assumed the role of chief executive officer of Bio-Works Sweden (BIOWKS.ST). He comes most recently from a role as Director of Instruments at Vironova AB and has a background in senior leadership roles within large-scale suppliers to the biopharmaceutical market including Millipore (now Merck-Millipore) and GE Healthcare Life Sciences (now Cytiva)."With deep industry experience and a proven track record of performance, Jonathan is the right leader to lead Bio-Works into the future as an innovator in downstream purification," said Peter Ehrenheim, chairman of the

Vator Securities: Bio-Works Technologies: Leaving randomness

Bio-Works’s net sales for full year 2019 were SEK 5.6 million, down SEK 1 million from 2018. The decrease is due to the fact that the company’s largest customer in 2018 did not place an order in 2019. In this update, we have looked beyond Bio-Works’s obvious stochastic character of the order inflow as we believe this is symptomatic for all early commercialization stage companies and not a structural problem for Bio-Works as such. Here is our case: the company’s largest customer accounted for SEK 3.8 million of the SEK 6.6 million in 2018 revenues. Excluding the orders from the largest

There are no items matching the current filter
There are no more items matching the current filter
Back to top